Biotechnology

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

Novartis unveils groundbreaking Phase III data for Rhapsido, offering hope as the first potential targeted therapy for 29 million chronic hive sufferers.

With a new CMO, Get A Drip is capitalizing on the longevity trend. But as it expands, it faces questions on scientific rigor and regulatory oversight.

Elixiron's enrupatinib shows promise in targeting neuroinflammation, with early data suggesting cognitive benefits and a new biomarker-guided path for therapy.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

Xeris Biopharma secures a new patent for its rare disease drug KEVEYIS until 2039, a strategic move to fend off generic competition and lock in revenue.

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

Leveraged finance titans turned a personal fight into a philanthropic powerhouse, raising a record $4.3M to fund the science that’s turning the tide on melanoma.

Wellness brands often struggle to turn concepts into viable products. A Utah-based CDMO's new PhD-led center is bridging the gap from science to scale.

Abridge unveils a sweeping AI platform to combat clinician burnout and mend a fragmented system by linking care delivery, payment, and research.

In memory of her daughter Elora, a mother's foundation joins a global research network, turning personal tragedy into a collaborative fight against a rare cancer.

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

Probiogen's 'Probiotic of the Year' award isn't just a win for the brand; it marks a pivotal moment for functional supplements and conscious consumerism.

Despite a dip in NAV, Northern Venture Trust raises £30M and maintains dividends, bracing for the impact of a major VCT tax relief cut on UK startups.

An Arizona nonprofit’s innovative sweepstakes, driven by a personal mission, is accelerating gene therapy for childhood blindness. A new model for impact.

A projected 14.9% CAGR signals a gold rush in Alzheimer's agitation treatment. New, safer drugs are replacing risky antipsychotics, offering hope to millions.

With a promising cancer therapy but precarious finances, Propanc Biopharma's stock buyback raises a critical question: is it a sign of confidence or a high-stakes gamble?